A Phase 1 interventional study of Calderasib and PPI in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effect of food, formulation, and a PPI on the levels of calderasib in a person's body over time.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive calderasib on Day 1 on an empty stomach
Drug: Calderasib
Participants will receive calderasib on Day 1 after a high-fat/high-calorie breakfast
Drug: Calderasib
Participants will receive calderasib Formulation 1 on Day 1
Drug: Calderasib
Participants will receive calderasib Formulation 2 on Day 1
Drug: Calderasib
Participants will receive calderasib without a PPI on Day 1
Drug: Calderasib
Participants will receive calderasib with a PPI on Day 5
Drug: Calderasib · Drug: PPI
Oral Tablet
Also known as: MK-1084
Oral Capsule
Food effect: Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) of Calderasib
Blood samples will be collected to determine the AUC0-inf of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Food Effect: Maximum Plasma Concentration (Cmax) of Calderasib
Blood samples will be collected to determine the Cmax of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Formulation Effect: Area Under the Concentration-Time Curve from 0 to the Time of the Last Quantifiable Sample (AUC0-last) of Calderasib
Blood samples will be collected to determine the AUC0-last of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Formulation Effect: AUC0-inf of Calderasib
Blood samples will be collected to determine the AUC0-inf of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Formulation Effect: Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of Calderasib
Blood samples will be collected to determine the AUC0-24 of calderasib.
Time frame: At designated timepoints (up to 24 hours postdose)
Formulation Effect: Cmax of Calderasib
Blood samples will be collected to determine the Cmax of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Formulation Effect: Plasma Concentration at 24 hours (C24) of Calderasib
Blood samples will be collected to determine the C24 of calderasib.
Time frame: 24 hours postdose
Formulation Effect: Lag Time (tlag) of Calderasib
Blood samples will be collected to determine the tlag of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Formulation Effect: Time to Maximum Plasma Concentration (Tmax) of Calderasib
Blood samples will be collected to determine the Tmax of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Formulation Effect: Apparent Terminal Half-Life (t1/2) of Calderasib
Blood samples will be collected to determine the t1/2 of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Formulation Effect: Apparent Clearance (CL/F) of Calderasib
Blood samples will be collected to determine the CL/F of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Formulation Effect: Apparent Volume of Distribution During Terminal Phase (Vz/F) of Calderasib
Blood samples will be collected to determine the Vz/F of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Proton Pump Inhibitor (PPI) Effect: AUC0-inf of Calderasib
Blood samples will be collected to determine the AUC0-inf of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
PPI Effect: Cmax of Calderasib
Blood samples will be collected to determine the Cmax of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Food Effect: AUC0-last of Calderasib
Blood samples will be collected to determine the AUC0-last of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Food Effect: AUC0-24 of Calderasib
Blood samples will be collected to determine the AUC0-24 of calderasib.
Time frame: At designated timepoints (up to 24 hours postdose)
Food Effect: C24 of Calderasib
Blood samples will be collected to determine the C24 of calderasib.
Time frame: 24 hours postdose
Food Effect: tlag of Calderasib
Blood samples will be collected to determine the tlag of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Food Effect: Tmax of Calderasib
Blood samples will be collected to determine the Tmax of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Food Effect: t1/2 of Calderasib
Blood samples will be collected to determine the t1/2 of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Food Effect: CL/F of Calderasib
Blood samples will be collected to determine the CL/F of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Food Effect: Vz/F of Calderasib
Blood samples will be collected to determine the Vz/F of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
Food Effect: Number of Participants Who Experience a Treatment Emergent Adverse Event (TEAE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 2 months
Food Effect: Number of Participants Who Discontinue Study Treatment Due to a TEAE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 2 months
Formulation Effect: Number of Participants Who Experience a TEAE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 2 months
Formulation Effect: Number of Participants Who Discontinue Study Treatment Due to a TEAE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 2 months
PPI Effect: AUC0-last of Calderasib
Blood samples will be collected to determine the AUC0-last of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
PPI Effect: AUC0-24 of Calderasib
Blood samples will be collected to determine the AUC0-24 of calderasib.
Time frame: At designated timepoints (up to 24 hours postdose)
PPI Effect: C24 of Calderasib
Blood samples will be collected to determine the C24 of calderasib.
Time frame: 24 hours postdose
PPI Effect: tlag of Calderasib
Blood samples will be collected to determine the tlag of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
PPI Effect: Tmax of Calderasib
Blood samples will be collected to determine the Tmax of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
PPI Effect: t1/2 of Calderasib
Blood samples will be collected to determine the t1/2 of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
PPI Effect: CL/F of Calderasib
Blood samples will be collected to determine the CL/F of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
PPI Effect: Vz/F of Calderasib
Blood samples will be collected to determine the Vz/F of calderasib.
Time frame: At designated timepoints (up to 48 hours postdose)
PPI Effect: Number of Participants Who Experience a TEAE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 2 months
PPI Effect: Number of Participants Who Discontinue Study Treatment Due to a TEAE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 2 months
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2023 to primary completion in Nov 2023, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Calderasib